New drug cocktail shows promise for cervical cancer before surgery

NCT ID NCT07055399

Recruiting now Disease control Sponsor: Fujian Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial is testing whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) along with chemotherapy before surgery can help shrink tumors in people with locally advanced cervical cancer. The study will enroll 43 participants and measure how many have no cancer cells left at the time of surgery. It is an early-stage study, so results are not yet proven.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iparomlimab and tuvonralimab (a dual PD-1/CTLA-4 blocker) plus cisplatin and nab-paclitaxel chemotherapy
What this could lead to: If successful, this approach could offer a more effective way to shrink tumors before surgery, potentially improving long-term outcomes for patients with locally advanced cervical cancer.
What could go wrong: This is a small, early-phase trial (43 participants) with no control group, so results may not be definitive. The drug combination may cause significant side effects, and not all patients may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED CERVICAL CANCER

Contacts and locations

Locations

Fujian Cancer Hospital
RECRUITING

Fuzhou, Fujian, 350014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.